Market closed
Annovis Bio/$ANVS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Annovis Bio
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
Ticker
$ANVS
Sector
Trading on
NYSE
Industry
Biotechnology
Headquarters
Employees
11
Website
Annovis Bio Metrics
BasicAdvanced
$82M
Market cap
-
P/E ratio
-$3.97
EPS
1.70
Beta
-
Dividend rate
Price and volume
Market cap
$82M
Beta
1.7
52-week high
$22.49
52-week low
$4.53
Average daily volume
249K
Financial strength
Current ratio
2.664
Quick ratio
2.344
Management effectiveness
Return on assets (TTM)
-154.58%
Return on equity (TTM)
-596.70%
Valuation
Price to book
11.21
Price to tangible book (TTM)
11.21
Price to free cash flow (TTM)
-2.861
Growth
Earnings per share change (TTM)
-18.31%
3-year earnings per share growth (CAGR)
41.35%
What the Analysts think about Annovis Bio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Annovis Bio stock.
Annovis Bio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Annovis Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Annovis Bio News
AllArticlesVideos
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace
GlobeNewsWire·1 week ago
Annovis to Host Year-End Investor Webcast on December 11, 2024
GlobeNewsWire·3 weeks ago
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Annovis Bio stock?
Annovis Bio (ANVS) has a market cap of $82M as of December 13, 2024.
What is the P/E ratio for Annovis Bio stock?
The price to earnings (P/E) ratio for Annovis Bio (ANVS) stock is 0 as of December 13, 2024.
Does Annovis Bio stock pay dividends?
No, Annovis Bio (ANVS) stock does not pay dividends to its shareholders as of December 13, 2024.
When is the next Annovis Bio dividend payment date?
Annovis Bio (ANVS) stock does not pay dividends to its shareholders.
What is the beta indicator for Annovis Bio?
Annovis Bio (ANVS) has a beta rating of 1.7. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.